Pharmaceutical

Grünenthal gains Valinor Pharma and constipation drug Movantik

Grünenthal has announced the acquisition of Valinor Pharma and its opioid-induced constipation (OIC) therapy Movantik for $250m.

Jul 24, 2024 - 04:00
Grünenthal gains Valinor Pharma and constipation drug Movantik
Grünenthal has announced the acquisition of Valinor Pharma and its opioid-induced constipation (OIC) therapy Movantik for $250m.
Read the original article

Tags:

Previous Article

Johnson & Johnson submits sNDA for SPRAVATO to treat depression

Next Article

UNAIDS boss calls on Gilead to provide ‘miracle’ drug to developing countries

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: USDA to push food producers to substantiate claims that animals are raised without antibiotics

STAT+: USDA to push food producers to substantiate clai...

Jun 16, 2023

Generics expected to improve access for patients with idiopathic pulmonary fibrosis

Generics expected to improve access for patients with i...

Sep 27, 2023

Erasca trims workforce and pipeline to focus on KRAS and molecular glues

Erasca trims workforce and pipeline to focus on KRAS an...

May 19, 2024